Free delivery over $3201–3 day express deliveryDispatched Australia-wideIndependent lab reports published
Free bac water with any 2 vials · no code · ends Thu 26 NovBlack Fridayopens Fri 27 Nov ·  
Shop now

ARA-290 – 10mg

$80.00

ARA-290 10mg (Cibinetide) is an investigational erythropoietin-derived peptide studied in tissue-protective signalling, inflammatory pathways and experimental neuropathy research.

Available from Peps Aussie Australia for controlled laboratory research and analytical applications.

  • Product: ARA-290 (Cibinetide)
  • Size: 10mg
  • Peptide Type: Synthetic erythropoietin-derived peptide
  • Commonly Described Length: 11 amino acid residues
  • Research Areas: Tissue-protective signalling, inflammatory biology and small nerve fibre research
  • Parent Molecule: Erythropoietin (EPO)
  • Quality Documentation: Available Certificates of Analysis (COA)
  • Shipping: Australian dispatch, subject to stock availability
  • Intended Use: Scientific and laboratory research only

For laboratory research use only. Not intended for human or animal consumption, administration, nerve repair or therapeutic use.

Free Delivery on all orders above $320

Out of stock

Description

ARA-290 10mg – Cibinetide Erythropoietin-Derived Research Peptide Australia

ARA-290 10mg, also known as cibinetide, is an investigational erythropoietin-derived peptide listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled experimental research.

ARA-290 was developed to investigate biological signalling associated with tissue protection and cellular responses to injury.

The peptide is derived from a region of erythropoietin (EPO), a naturally occurring glycoprotein hormone best known for its role in regulating red blood cell production.

Unlike conventional erythropoietin, ARA-290 was designed to investigate tissue-protective signalling without the same red-cell-stimulating activity.

Scientific research involving ARA-290 has examined inflammatory pathways, cellular injury responses, neuronal biology and tissue-protective signalling.

Clinical investigations using specifically manufactured investigational formulations have also explored neuropathy-related endpoints, including research involving small nerve fibres and sensory function.

However, ARA-290 remains an investigational compound, and the available evidence does not establish that independently supplied ARA-290 material safely or effectively treats neuropathy, inflammation or tissue injury.

Published clinical results relate to particular investigational formulations, manufacturing processes and controlled research conditions.

They do not independently verify the identity, composition, safety or clinical suitability of material supplied by an unrelated source.

Peps Aussie lists ARA-290 in a nominal 10mg size for laboratory research and analytical applications.

Important: ARA-290 is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, nerve repair, therapeutic use or clinical treatment.

What Is ARA-290?

ARA-290, also known as cibinetide, is a synthetic peptide derived from the structure of erythropoietin.

It is commonly described as an 11-amino-acid peptide designed to investigate the tissue-protective signalling properties associated with erythropoietin-derived molecules.

ARA-290 is distinct from full-length erythropoietin.

The peptide has been investigated in relation to a proposed tissue-protective receptor system associated with the erythropoietin receptor and the beta-common receptor, also known as CD131.

This proposed receptor mechanism has been explored in experimental research, although its precise molecular composition and signalling behaviour remain subjects of scientific investigation.

Relevant research areas include:

  • Tissue-protective signalling.
  • Inflammatory pathway regulation.
  • Neuronal injury responses.
  • Small nerve fibre research.
  • Experimental neuropathy models.
  • Cellular stress responses.
  • Erythropoietin-derived peptide pharmacology.
  • Analytical peptide characterisation.

These areas describe scientific research topics rather than established therapeutic effects.

Understanding Erythropoietin and Tissue-Protective Signalling

Erythropoietin is a naturally occurring glycoprotein hormone involved in regulating red blood cell production.

Its conventional haematopoietic activity is associated with erythropoietin receptor signalling in erythroid precursor cells.

Researchers have also investigated whether erythropoietin-related molecules participate in signalling pathways associated with tissue responses to injury.

ARA-290 was developed as part of efforts to investigate these proposed tissue-protective mechanisms separately from conventional red-cell stimulation.

However, the design objective of separating these activities does not establish that a particular research preparation is clinically safe or free from haematological effects.

ARA-290 Peptide Research and Scientific Applications

Published research involving ARA-290 spans experimental tissue-protective signalling, inflammatory biology, neuronal research and clinical investigation.

The following sections describe scientific research topics rather than proven therapeutic effects of the Peps Aussie material.

1. Tissue-Protective Signalling Research

One of the principal areas associated with ARA-290 research involves tissue-protective signalling.

Tissue-protective pathways are investigated in relation to cellular responses to injury, inflammation and physiological stress.

Experimental studies involving erythropoietin-derived peptides have examined molecular pathways associated with these processes.

Relevant research topics include:

  • Cellular injury responses.
  • Tissue-associated signalling.
  • Experimental injury models.
  • Molecular regulatory pathways.
  • Cell survival-associated mechanisms.
  • Inflammatory responses.
  • Peptide-associated cellular signalling.

These investigations contribute to understanding possible tissue-protective mechanisms.

However, laboratory findings do not establish that ARA-290 prevents or repairs tissue damage in humans.

2. Inflammatory Signalling Research

Inflammatory signalling involves interactions between immune cells, cytokines and molecular regulatory pathways.

Experimental research involving ARA-290 has examined inflammatory-associated processes in selected models.

Relevant scientific topics include:

  • Cytokine-associated pathways.
  • Cellular inflammatory responses.
  • Immune-associated signalling.
  • Experimental inflammatory models.
  • Molecular pathway regulation.
  • Peptide-associated cellular responses.

These investigations contribute to understanding the relationship between erythropoietin-derived peptides and inflammatory biology.

They do not establish that ARA-290 is an approved anti-inflammatory treatment.

3. Small Fibre Neuropathy Research

Small fibre neuropathy involves dysfunction or damage affecting small peripheral nerve fibres.

These fibres participate in sensory and autonomic functions.

Clinical research involving investigational cibinetide formulations has examined neuropathy-related endpoints, including small nerve fibre measurements.

Relevant research topics include:

  • Small nerve fibre biology.
  • Peripheral nerve-associated measurements.
  • Sensory function.
  • Neuropathy-related clinical endpoints.
  • Nerve fibre density assessments.
  • Experimental neuronal signalling.

These investigations contribute to scientific understanding of neuropathy-associated processes.

However, clinical findings do not establish that independently supplied ARA-290 material treats small fibre neuropathy.

4. Peripheral Nervous System Research

The peripheral nervous system consists of nerves and associated structures outside the brain and spinal cord.

Research involving ARA-290 has explored neuronal and peripheral nerve-associated pathways.

Relevant research topics include:

  • Peripheral nerve biology.
  • Neuronal stress responses.
  • Experimental nerve injury models.
  • Sensory-associated signalling.
  • Cellular survival pathways.
  • Tissue-associated inflammatory responses.

These investigations provide context for understanding the biological mechanisms explored in ARA-290 research.

However, experimental observations do not establish clinically meaningful nerve regeneration or neurological recovery in humans.

5. Erythropoietin Receptor and CD131 Research

ARA-290 has been investigated in relation to a proposed tissue-protective receptor complex involving the erythropoietin receptor and the beta-common receptor, CD131.

This proposed mechanism is distinct from conventional erythropoietin-associated red blood cell stimulation.

Relevant research topics include:

  • Erythropoietin receptor biology.
  • CD131-associated signalling.
  • Receptor complex formation.
  • Cellular response pathways.
  • Ligand–receptor interactions.
  • Experimental receptor pharmacology.

These investigations contribute to understanding the molecular mechanisms proposed for erythropoietin-derived peptides.

However, the exact receptor composition and signalling mechanism remain scientifically complex and should not be treated as conclusively established across all biological systems.

6. Cellular Stress and Injury Response Research

Cellular stress responses involve molecular pathways activated by environmental or physiological challenges.

Experimental studies involving ARA-290 and related peptides have examined cellular responses to injury-associated conditions.

Relevant research topics include:

  • Cellular stress signalling.
  • Experimental injury models.
  • Inflammatory-associated pathways.
  • Cell survival-associated mechanisms.
  • Tissue response biology.
  • Molecular regulatory processes.

These investigations contribute to understanding how cells respond to injury-related conditions.

However, findings from isolated cells or animal models cannot automatically be generalised to human clinical outcomes.

7. ARA-290 Compared With Erythropoietin

ARA-290 is structurally related to erythropoietin but is chemically and pharmacologically distinct.

ARA-290 / Cibinetide:

  • An investigational erythropoietin-derived peptide.
  • Commonly described as an 11-amino-acid peptide.
  • Developed to investigate tissue-protective signalling.
  • Designed to minimise conventional red-cell-stimulating activity.
  • Has been examined in preclinical and clinical research.

Erythropoietin (EPO):

  • A naturally occurring glycoprotein hormone.
  • Regulates red blood cell production.
  • Has established pharmaceutical applications in certain conditions.
  • Has a substantially different molecular structure.
  • Acts through well-characterised haematopoietic signalling pathways.

Research findings involving erythropoietin should not automatically be attributed to ARA-290.

Likewise, the established pharmaceutical uses of erythropoietin do not establish therapeutic approval for ARA-290.

8. ARA-290 Analytical Characterisation and Quality Research

ARA-290 is also relevant to analytical investigations involving synthetic peptide identity, structure and material quality.

Laboratories evaluating ARA-290 may investigate:

  • Confirmation of the declared amino acid sequence.
  • Molecular mass determination.
  • Terminal group characterisation.
  • Chromatographic purity profiles.
  • Related peptide impurities.
  • Quantitative content determination.
  • Stability and degradation characteristics.
  • Batch-to-batch analytical consistency.
  • Comparison with verified reference standards.

Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS) and other suitable methods.

A chromatographic purity result alone does not establish that an independently supplied research peptide is chemically equivalent to a formulation used in published clinical studies.

ARA-290 10mg Research Peptide Specifications

Peps Aussie lists ARA-290 in a nominal 10mg size.

Specification Details
Product name ARA-290
Alternative name Cibinetide
Listed size 10mg
Peptide type Synthetic erythropoietin-derived peptide
Commonly described length 11 amino acid residues
Parent molecule Erythropoietin (EPO)
Research category Tissue-protective signalling and experimental neurobiology
Research areas Inflammatory signalling, small nerve fibre research and cellular injury responses
Proposed receptor research Erythropoietin receptor and CD131-associated pathways
Supplier Peps Aussie Australia
Intended use Laboratory research and analytical investigation only

The scientific characteristics above describe ARA-290 as discussed in published research. They do not independently verify the identity, composition, purity or content of the supplied material.

Exact molecular identity, amino acid sequence, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.

Important: The name ARA-290 or cibinetide does not independently establish that an unrelated research preparation is identical to the investigational material used in clinical studies.

ARA-290 Certificate of Analysis (COA) and Quality Documentation

Analytical verification is particularly important when evaluating research materials associated with investigational pharmaceutical compounds.

Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.

View Peps Aussie Certificates of Analysis

When evaluating ARA-290 analytical documentation, researchers should consider:

  • Peptide identity: Whether testing supports the declared ARA-290 identity.
  • Sequence verification: Whether the amino acid sequence has been established.
  • Terminal modifications: Whether the peptide’s terminal groups have been characterised.
  • Molecular mass: Whether testing supports the expected molecular characteristics.
  • Purity assessment: Whether suitable methods were used to evaluate impurities.
  • Content determination: Whether quantitative testing supports the declared 10mg quantity.
  • Batch traceability: Whether the certificate corresponds to the supplied production lot.
  • Testing methodology: Whether the analytical techniques are appropriate for the peptide.
  • Additional testing: Whether relevant contamination or other quality assessments were performed.

High-performance liquid chromatography and mass spectrometry are commonly used in peptide characterisation.

A certificate should be interpreted according to the tests actually performed.

The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.

ARA-290 Storage and Laboratory Handling

Research peptides require appropriate handling to support sample integrity and experimental reproducibility.

Storage requirements for ARA-290 depend on the molecular structure, formulation, packaging and validated manufacturer stability information.

Laboratories should consider:

  • Appropriate storage temperature.
  • Protection from light and moisture where necessary.
  • Suitable laboratory containers.
  • Compatibility with analytical solvents.
  • Stability following sample preparation.
  • Potential degradation during storage.
  • Appropriate laboratory handling and disposal procedures.

No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.

Storage or preparation information from clinical trial formulations should not automatically be applied to independently supplied research materials.

All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.

ARA-290 10mg Australia – Product Availability and Shipping

Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.

ARA-290 10mg is the currently listed nominal product size.

Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.

For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.

Frequently Asked Questions About ARA-290

What is ARA-290?

ARA-290, also known as cibinetide, is an investigational erythropoietin-derived peptide developed to investigate tissue-protective signalling.

What is ARA-290 studied for?

Preclinical and clinical research has examined ARA-290 in relation to inflammatory signalling, tissue-protective pathways and neuropathy-associated endpoints.

Is ARA-290 the same as cibinetide?

Yes. Cibinetide is an alternative name associated with ARA-290.

Is ARA-290 the same as erythropoietin?

No. ARA-290 is a short synthetic peptide derived from erythropoietin-associated structural research. It is not chemically equivalent to full-length erythropoietin.

Does ARA-290 stimulate red blood cell production?

ARA-290 was designed to investigate tissue-protective signalling without conventional erythropoietin-associated red-cell stimulation. However, this design objective does not establish the safety or haematological profile of independently supplied research material.

Is ARA-290 studied for neuropathy?

Yes. Clinical investigations using specifically manufactured cibinetide formulations have examined neuropathy-related endpoints, including small nerve fibre measurements.

Does ARA-290 repair nerves?

The available evidence does not establish that independently supplied ARA-290 material repairs nerves or produces clinically meaningful neurological recovery.

Is ARA-290 an anti-inflammatory peptide?

ARA-290 has been investigated in experimental inflammatory signalling research. However, this does not establish that it is an approved or clinically validated anti-inflammatory treatment.

Has ARA-290 been studied in humans?

Yes. Clinical studies involving investigational cibinetide formulations have examined selected neuropathy-related and inflammatory endpoints. These findings do not validate unrelated research preparations.

What size does Peps Aussie list?

Peps Aussie lists ARA-290 in a 10mg nominal size. Researchers should verify the individual vial label and supporting analytical documentation.

Does ARA-290 have a Certificate of Analysis?

Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.

How should ARA-290 be stored?

Storage requirements depend on the formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.

Is ARA-290 approved for human or veterinary use?

No medical or veterinary approval is claimed for the Peps Aussie ARA-290 research product.

This product is not supplied for human or animal consumption, administration, diagnosis, prevention or treatment.

ARA-290 Research Peptides at Peps Aussie Australia

Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, peptide chemistry and experimental cellular signalling.

ARA-290 remains a subject of scientific interest because of its relationship with erythropoietin-derived peptide research and its investigation in tissue-protective signalling, inflammatory pathways and neuropathy-associated clinical endpoints.

Researchers evaluating ARA-290 10mg should prioritise accurate peptide identification, appropriate analytical documentation, batch traceability and validated laboratory procedures.

Explore the Peps Aussie research catalogue at pepsaussie.com.


Research Use Only Disclaimer

ARA-290 10mg is intended strictly for laboratory research and analytical purposes only.

This product is not intended for human or animal consumption, injection, administration, nerve repair, therapeutic use or clinical treatment.

Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish neuropathy treatment, nerve regeneration, anti-inflammatory benefits, tissue repair, clinical safety or therapeutic suitability for the material offered.

Clinical findings involving specifically manufactured investigational cibinetide formulations do not establish the identity, quality or clinical suitability of independently supplied research material.

No dosing, self-administration or therapeutic guidance is provided.

Additional information

Size

10mg

Reviews

There are no reviews yet.

Reviews here are by invitation. We email a link once your order has arrived, so every review comes from someone who received the product. Lost the email? Find your review link.

Related Products

Search Products